Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101760 | 0.82 | PTGDR2 (0.45) | PTGDR2PTGS2MAPK14CYP17A1MAPK13 | |
| SCHEMBL5205345 | 0.71 | TGFBR1 (0.53) | MAPK14EGFRMAPK13MAPK12MAPK11 | |
| SCHEMBL2798070 | 0.68 | MAPK14 (0.72) | PTGS2MAPK14 | |
| SCHEMBL2792366 | 0.67 | PTGDR2 (0.47) | PTGDR2PTGS2MAPK14EGFRRAF1 | |
| SCHEMBL6420068 | 0.67 | SMN1; SMN2 (0.72) | CYP17A1SMN1; SMN2 | |
| SCHEMBL2340312 | 0.66 | CYP17A1 (0.44) | MAPK14CYP17A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9030540 | 0.66 | SMN1; SMN2 (0.70) | CYP17A1SMN1; SMN2 | |
| SCHEMBL2335564 | 0.65 | CYP17A1 (0.40) | MAPK14CYP17A1SMN1; SMN2 | |
| SCHEMBL4092218 | 0.64 | ADORA2B (0.52) | PTGS2MAPK14ADORA2BNQO2ADORA2A | |
| SCHEMBL4103384 | 0.64 | ALDH1A1 (0.57) | MAPK14ADORA2BADORA2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | PTGDR2 2625/4885PTGS2 1566/4885MAPK14 136/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | PTGDR2 2625/4885PTGS2 1566/4885MAPK14 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.